Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.

Literature DB >> 27655868

A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.

Leslie Goo¹, Kimberly A Dowd¹, Tsai-Yu Lin¹, John R Mascola², Barney S Graham², Julie E Ledgerwood², Theodore C Pierson¹.

Abstract

Chikungunya virus (CHIKV) is an alphavirus that has emerged as a global health burden. There are 3 CHIKV genotypes: Asian, West African, and Eastern/Central/South African. No licensed CHIKV vaccine is available, and whether the antibody response elicited by one genotype can neutralize heterologous genotypes is unclear. We assessed neutralizing antibody (NAb) responses of volunteers in a phase 1 study of a CHIKV vaccine against 9 viral strains representing all 3 genotypes. Minimal differences in vaccine-elicited NAb responses were observed among genotypes, suggesting that vaccination with a single CHIKV strain can elicit cross-protective NAbs against all 3 genotypes. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities: Chemical Species

Keywords: chikungunya virus; neutralizing antibodies; virus-like particle vaccine

Mesh：

Substances：

Year: 2016 PMID： 27655868 PMCID： PMC5091377 DOI： 10.1093/infdis/jiw431

Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226

15 in total

Review 1. Occupancy and mechanism in antibody-mediated neutralization of animal viruses.

Authors: P J Klasse; Q J Sattentau
Journal: J Gen Virol Date: 2002-09 Impact factor: 3.891

2. Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic.

Authors: Vidya A Arankalle; Shubham Shrivastava; Sarah Cherian; Rashmi S Gunjikar; Atul M Walimbe; Santosh M Jadhav; A B Sudeep; Akhilesh C Mishra
Journal: J Gen Virol Date: 2007-07 Impact factor: 3.891

Review 3. Emergence of chikungunya virus in Indian subcontinent after 32 years: A review.

Authors: Chandrakant Lahariya; S K Pradhan
Journal: J Vector Borne Dis Date: 2006-12 Impact factor: 1.688

4. Chikungunya in the Americas.

Authors: Isabelle Leparc-Goffart; Antoine Nougairede; Sylvie Cassadou; Christine Prat; Xavier de Lamballerie
Journal: Lancet Date: 2014-02-08 Impact factor: 79.321

Review 5. Therapeutics and vaccines against chikungunya virus.

Authors: Tero Ahola; Therese Couderc; Therese Courderc; Lisa F P Ng; David Hallengärd; Ann Powers; Marc Lecuit; Mariano Esteban; Andres Merits; Pierre Roques; Peter Liljeström
Journal: Vector Borne Zoonotic Dis Date: 2015-04 Impact factor: 2.133

Review 6. Interspecies transmission and chikungunya virus emergence.

Authors: Konstantin A Tsetsarkin; Rubing Chen; Scott C Weaver
Journal: Curr Opin Virol Date: 2016-03-14 Impact factor: 7.090

7. A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006.

Authors: Philippe Renault; Jean-Louis Solet; Daouda Sissoko; Elsa Balleydier; Sophie Larrieu; Laurent Filleul; Christian Lassalle; Julien Thiria; Emmanuelle Rachou; Henriette de Valk; Daniele Ilef; Martine Ledrans; Isabelle Quatresous; Philippe Quenel; Vincent Pierre
Journal: Am J Trop Med Hyg Date: 2007-10 Impact factor: 2.345

Review 8. Factors responsible for the emergence of arboviruses; strategies, challenges and limitations for their control.

Authors: Guodong Liang; Xiaoyan Gao; Ernest A Gould
Journal: Emerg Microbes Infect Date: 2015-03-25 Impact factor: 7.163

9. A single mutation in chikungunya virus affects vector specificity and epidemic potential.

Authors: Konstantin A Tsetsarkin; Dana L Vanlandingham; Charles E McGee; Stephen Higgs
Journal: PLoS Pathog Date: 2007-12 Impact factor: 6.823

10. Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus.

Authors: Karuppiah Muthumani; Peter Block; Seleeke Flingai; Nagarajan Muruganantham; Itta Krishna Chaaithanya; Colleen Tingey; Megan Wise; Emma L Reuschel; Christopher Chung; Abirami Muthumani; Gopalsamy Sarangan; Padma Srikanth; Amir S Khan; Paluru Vijayachari; Niranjan Y Sardesai; J Joseph Kim; Kenneth E Ugen; David B Weiner
Journal: J Infect Dis Date: 2016-03-21 Impact factor: 5.226

21 in total

1. The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates.

Authors: Natalie A Prow; Liang Liu; Mary K McCarthy; Kevin Walters; Raj Kalkeri; Jillian Geiger; Fusataka Koide; Tamara H Cooper; Preethi Eldi; Eri Nakayama; Kerrilyn R Diener; Paul M Howley; John D Hayball; Thomas E Morrison; Andreas Suhrbier
Journal: NPJ Vaccines Date: 2020-06-02 Impact factor: 7.344

Review 2. 51 years in of Chikungunya clinical vaccine development: A historical perspective.

Authors: Arturo Reyes-Sandoval
Journal: Hum Vaccin Immunother Date: 2019-04-02 Impact factor: 3.452

Review 3. Vaccine and Therapeutic Options To Control Chikungunya Virus.

Authors: Ann M Powers
Journal: Clin Microbiol Rev Date: 2017-12-13 Impact factor: 26.132

Review 4. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.

Authors: Laurie A Silva; Terence S Dermody
Journal: J Clin Invest Date: 2017-03-01 Impact factor: 14.808

Review 5. Chikungunya fever: a threat to global public health.

Authors: Raíza Nara Cunha Moizéis; Thales Allyrio Araújo de Medeiros Fernandes; Paulo Marcos da Matta Guedes; Hannaly Wana Bezerra Pereira; Daniel Carlos Ferreira Lanza; Judson Welber Veríssimo de Azevedo; Josélio Maria de Araújo Galvão; José Veríssimo Fernandes
Journal: Pathog Glob Health Date: 2018-05-28 Impact factor: 2.894

6. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes.

Authors: Julie M Fox; Vicky Roy; Bronwyn M Gunn; Ling Huang; Melissa A Edeling; Matthias Mack; Daved H Fremont; Benjamin J Doranz; Syd Johnson; Galit Alter; Michael S Diamond
Journal: Sci Immunol Date: 2019-02-22

7. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.

Authors: Grace L Chen; Emily E Coates; Sarah H Plummer; Cristina A Carter; Nina Berkowitz; Michelle Conan-Cibotti; Josephine H Cox; Allison Beck; Mark O'Callahan; Charla Andrews; Ingelise J Gordon; Brenda Larkin; Rebecca Lampley; Florence Kaltovich; Jason Gall; Kevin Carlton; Jason Mendy; Doug Haney; Jeanine May; Amy Bray; Robert T Bailer; Kimberly A Dowd; Brittanie Brockett; David Gordon; Richard A Koup; Richard Schwartz; John R Mascola; Barney S Graham; Theodore C Pierson; Yeycy Donastorg; Nicolas Rosario; Jean William Pape; Bruno Hoen; André Cabié; Clemente Diaz; Julie E Ledgerwood
Journal: JAMA Date: 2020-04-14 Impact factor: 56.272